jeudi 24 mars 2016

Development of low cost oral inactivated vaccines for dysentery

Okayama University researchers in collaboration with colleagues in India have developed inactivated vaccines a promising candidate for the production and commercialization of a low cost oral dysentery vaccine for use in developing countries.

Shin-ichi Miyoshi at the Okayama University Graduate School of Medicine and Dentistry and colleagues orally administered a mixture of the six major Shigella serotypes of heat-killed bacteria sample preparations to laboratory animals in order to study the possibility of developing inactivated vaccines. The researchers conducted experiments using both passive and active immunization experimental systems and observed protective effect against infections with sufficient immunity-inducing effect.

Furthermore, in tests using human cultured cells, the researchers did not find toxicity to the cells and observed strong production inducing immunity factors such as cytokines. This sample preparation has proved to be a promising candidate for oral dysentery vaccine. These sample preparations have proved to a promising candidate for the production and commercialization of a low cost oral dysentery vaccine. In the future, using the rhesus monkeys (natural host of Shigella), the researchers plan to study the protective and immunity-inducing effects as well as conducting clinical studies in Kolkata, India.

Background and expected outcome
Okayama University was selected by MEXT as the center for emerging and re-emerging infectious diseases research base formation program and in 2007 the university established the "Okayama University India Infection Joint Research Centre to contribute to the control of the many deaths due diarrhea (cholera, dysentery) in India. One of the research projects is on the development of inexpensive oral dysentery vaccine because of the lack of dysentery vaccines for practical use.

Dysentery destroys intestinal tissue because it is a diarrheal disease with severe bleeding with deaths in developing countries such as India, reaching 600 thousand people annually. For this reason, the World Health Organization has designated the development of dysentery vaccine to be one of the most urgent research areas. Today, drug resistant Shigella is spreading fast and its treatment and the control of dysentery is becoming increasingly difficult.
The results of this research are expected to lead to the development and commercialization of low-cost dysentery vaccines before the control of dysentery becomes extremely difficult.

Acknowledgments
The present study is being funded by the Education, Culture, Sports, Science and Technology Ministry (MEXT) as part of the emerging and re-emerging infectious diseases research COE program (FY 2007-2009); infectious disease research international network promotion program (FY 2010-2014); and National Research and Development Agency for the research and development mechanism infection (FY 2015).

Advertisement
The companies or research organizations, which cooperate to develop the low cost oral dysentery vaccines, are advertising widely.

Figure 1. Protective efficacy of the vaccine candidate in guinea pigs.

Figure 2. IgG secretion from peripheral blood mononuclear cells isolated from control or immunized rabbits.

Reference
Barman S, Koley H, Nag D, Shinoda S, Nair GB, Takeda Y. Passive immunity with multi-serotype heat-killed Shigellae in neonatal mice. Microbiology and Immunology, 58:463-466 (2014)
DOI. 10.1111/1348-0421.12164
http://ift.tt/1VKOWEj

Nag D, Sinha R, Mitra S, Barman S, Takeda Y, Shinoda S, Chakrabarti MK, Koley H. Heat killed multi-serotype Shigella immunogens induced humoral immunity and protection against heterologous challenge in rabbit model. Immunobiology, 220:1275-1283 (2015)
DOI. 10.1016/j.imbio.2015.07.002
http://ift.tt/1XQZroj

The 'Japan Initiative for Global Research Network on Infectious Diseases': a kickoff symposium (OKAYAMA UNIV. e-Bulletin Vol.13)
http://ift.tt/1VKOUwi

Combatting Infectious Diseases with Research Networks (OKAYAMA UNIV. e-Bulletin Vol.12)
http://ift.tt/1XQZssf

International research: Collaborative Research Center of Okayama University for Infectious Diseases in India (OKAYAMA UNIV. e-Bulletin Vol.7)
http://ift.tt/1VKOUwk

Vice President Shin-ichi Yamamato leads delegation to India to visit national research institutes and Okayama University-India collaborative research center (OKAYAMA UNIV. e-Bulletin Vol.3)
http://ift.tt/1XQZron

Correspondence to
Professor Shin-ichi Miyoshi, Ph.D.
Department of Environmental Health and Microbiology,
Graduate School of Medicine, Dentistry and Pharmaceutical
 Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku,
Okayama 700-8530, Japan
E-mail: [email protected]

Further information
Okayama University
1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan
Public Relations and Information Strategy
E-mail: [email protected]
Website: http://ift.tt/1ziUUkx
Okayama Univ. e-Bulletin: http://ift.tt/1NMLbtw
Okayama Univ. e-Bulletin (PDF Issues): http://ift.tt/1XQZrEB
About Okayama University (You Tube):
https://www.youtube.com/watch?v=iDL1coqPRYI
Okayama University Image Movie (You Tube):
https://www.youtube.com/watch?v=_WnbJVk2elA
https://www.youtube.com/watch?v=KU3hOIXS5kk

Okayama University Medical Research Updates (OU-MRU)
Vol.1:Innovative non-invasive 'liquid biopsy' method to capture circulating tumor cells from blood samples for genetic testing
Vol.2:Ensuring a cool recovery from cardiac arrest
Vol.3:Organ regeneration research leaps forward
Vol.4:Cardiac mechanosensitive integrator
Vol.5:Cell injections get to the heart of congenital defects
Vol.6:Fourth key molecule identified in bone development
Vol.7:Anticancer virus solution provides an alternative to surgery
Vol.8:Light-responsive dye stimulates sight in genetically blind patients
Vol.9:Diabetes drug helps towards immunity against cancer
Vol.10:Enzyme-inhibitors treat drug-resistant epilepsy
Vol.11:Compound-protein combination shows promise for arthritis treatment
Vol.12:Molecular features of the circadian clock system in fruit flies
Vol.13:Peptide directs artificial tissue growth
Vol.14:Simplified boron compound may treat brain tumours
Vol.15:Metamaterial absorbers for infrared inspection technologies
Vol.16:Epigenetics research traces how crickets restore lost limbs
Vol.17:Cell research shows pathway for suppressing hepatitis B virus
Vol.18:Therapeutic protein targets liver disease
Vol.19:Study links signalling protein to osteoarthritis
Vol.20:Lack of enzyme promotes fatty liver disease in thin patients
Vol.21:Combined gene transduction and light therapy targets gastric cancer
Vol.22:Medical supportive device for hemodialysis catheter puncture

Let's block ads! (Why?)

Development of low cost oral inactivated vaccines for dysentery

Aucun commentaire:

Enregistrer un commentaire